Identifying and clarifying the structural and compositional determinants that specifically contribute to Aβ sequestration by apoA-I-containing HDLs would not only provide a compelling insight into the requirements for effective Aβ binding, trafficking, and modulation, but may ultimately aid in the development and refinement of therapeutic interventions targeting AD. This evidence concerns the gene APOA1 and Alzheimer disease.